Disc Medicine Advances Pipeline with Key Clinical Milestones and Strong Cash Position

Event summary

  • Completed enrollment in Phase 3 APOLLO study of bitopertin for EPP, with topline data expected in Q4 2026.
  • Phase 2 data for DISC-0974 in myelofibrosis anemia to be presented at ASCO Annual Meeting in June 2026.
  • Phase 2 study of DISC-3405 in polycythemia vera and Phase 1b study in sickle cell disease progressing, with data expected in Q4 2026.
  • Strong financial position with $730 million in cash, cash equivalents, and marketable securities as of Q1 2026.

The big picture

Disc Medicine is advancing its pipeline with multiple clinical milestones, positioning itself for potential regulatory approvals and data readouts in the second half of 2026. The company's strong financial position provides a runway into 2029, supporting its strategy to address serious hematologic diseases through innovative therapeutic candidates. The upcoming data from key studies will be critical in shaping the company's future development and commercialization plans.

What we're watching

Regulatory Pathway
Whether the Phase 3 APOLLO study will support a successful resubmission and FDA approval for bitopertin by mid-2027.
Clinical Data
The impact of the Phase 2 data for DISC-0974 in myelofibrosis anemia and DISC-3405 in polycythemia vera and sickle cell disease on future development strategies.
Financial Management
The pace at which Disc Medicine will allocate its $730 million cash position to support multiple clinical programs and potential commercialization efforts.